Skip to main content

Advertisement

SpringerLink
Log in

Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Duloxetine is an effective therapeutic agent for chemotherapy-induced peripheral neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. Therefore, this retrospective study was performed to identify predictive factors of duloxetine response in CIPN patients to guide future strategies to improve the quality of life of patients undergoing chemotherapy. The participants were 74 cancer patients who were given duloxetine for relief of CIPN at our institute between October 2010 and January 2016. Variables were extracted from clinical records for regression analysis of factors related to relief of CIPN. We evaluated the effect of duloxetine 2 weeks after administration. Groups were categorized according to degree of improvement: poor, effective, and very effective. Multivariate ordered logistic regression analysis was performed to identify predictive factors for the usefulness of duloxetine. Threshold measures were examined using a receiver operating characteristic analysis (ROC) curve. Body height [odds ratio (OR) 0.943, 95% confidence interval (CI) 0.889–0.997; P = 0.0387], history of docetaxel use (OR 0.084, 95% Cl 0.009–0.814; P = 0.0325), and site of symptom (upper limb) (OR 3.848, 95% Cl 1.072–13.807; P = 0.0387) were significant factors related to the effect of duloxetine. ROC curve analysis of the poor effect group indicated a threshold for body height of >171.4 cm (area under the curve [AUC] = 0.61). In conclusion, body height (low), history of docetaxel use (less), and site of symptom (upper limb) were shown to be predictive factors for the usefulness of duloxetine for CIPN in patients undergoing chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Majithia N, Loprinzi CL, Smith TJ. New practical approaches to chemotherapy-induced neuropathic pain: prevention, assessment, and treatment. Oncology (Williston Park). 2016;30:1020–9.

    Google Scholar 

  2. Chu SH, Lee YJ, Lee ES, Geng Y, Wang XS, Cleeland CS. Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer. 2015;23:513–24.

    Article  PubMed  Google Scholar 

  3. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:1941–67.

    Article  CAS  PubMed  Google Scholar 

  4. Pachman DR, Watson JC, Loprinzi CL. Therapeutic strategies for cancer treatment related peripheral neuropathies. Curr Treat Options Oncol. 2014;15:567–80.

    Article  PubMed  Google Scholar 

  5. Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015;54:587–91.

    Article  CAS  PubMed  Google Scholar 

  6. Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22:2261–9.

    Article  PubMed  Google Scholar 

  7. Kanbayashi Y, Hosokawa T, Kitawaki J, Taguchi T. Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer. Anticancer Res. 2013;33:1153–6.

    PubMed  Google Scholar 

  8. Smith EM, Pang H, Ye C, Cirrincione C, Fleishman S, Paskett ED, et al. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial—CALGB/alliance 170601. Eur J Cancer Care (Engl). 2017. doi:10.1111/ecc.12421.

    Google Scholar 

  9. Aziz MT, Good BL, Lowe DK. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. Ann Pharmacother. 2014;48:626–32.

    Article  PubMed  Google Scholar 

  10. Piccolo J, Kolesar JM. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am J Health Syst Pharm. 2014;71:19–25.

    Article  CAS  PubMed  Google Scholar 

  11. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K, et al. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol. 2015;20:866–71.

    Article  CAS  PubMed  Google Scholar 

  13. Otake A, Yoshino K, Ueda Y, Sawada K, Mabuchi S, Kimura T, et al. Usefulness of duloxetine for paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients. Anticancer Res. 2015;35:359–63.

    CAS  PubMed  Google Scholar 

  14. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96:644–7.

    Article  PubMed  Google Scholar 

  15. Cheng YJ, Gregg EW, Kahn HS, Williams DE, De Rekeneire N, Narayan KM. Peripheral insensate neuropathy—a tall problem for US adults? Am J Epidemiol. 2006;164:873–80.

    Article  PubMed  Google Scholar 

  16. Kote GS, Bhat AN, K T, Ismail MH, Gupta A. Peripheral insensate neuropathy—is height a risk factor? J Clin Diagn Res. 2013;7:296–301.

    PubMed  Google Scholar 

  17. Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain. 2016;157:560–8.

    Article  CAS  PubMed  Google Scholar 

  18. Krøigård T, Schrøder HD, Qvortrup C, Eckhoff L, Pfeiffer P, Gaist D, Sindrup SH. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur J Neurol. 2014;21:623–9.

    Article  PubMed  Google Scholar 

  19. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24:1633–42.

    Article  CAS  PubMed  Google Scholar 

  20. Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T, et al. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs. 2010;21:877–81.

    Article  CAS  PubMed  Google Scholar 

  21. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014;40:872–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Hospital Pharmacy, Kyoto Prefectural University of Medicine, Kawaramachi Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan

    Yuko Kanbayashi

  2. Departments of Pain Treatment and Palliative Care Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan

    Yuko Kanbayashi, Hiroshi Ueno & Toyoshi Hosokawa

  3. Departments of Pain Management and Palliative Care Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan

    Megumi Inagaki, Hiroshi Ueno & Toyoshi Hosokawa

  4. Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, Kyoto, Japan

    Megumi Inagaki

Authors
  1. Yuko Kanbayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Megumi Inagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toyoshi Hosokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuko Kanbayashi.

Ethics declarations

Conflict of interest

Author declares that there is no conflict of interests.

Ethical approval

Approval was obtained from Ethics Review Boards of Kyoto Prefectural University of Medicine. All procedures were performed in accordance with the ethical standards of the Kyoto Prefectural University of Medicine Institutional Ethics Review Board and the 1964 Helsinki Declaration and its later amendments. No prospective studies with human participants or animals were performed by any of the authors for this article.

Informed consent

Informed consent was waived for individual participants included in the study given the retrospective nature of this work and in accordance with Kyoto Prefectural University of Medicine Institutional Review Board standards.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kanbayashi, Y., Inagaki, M., Ueno, H. et al. Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy. Med Oncol 34, 137 (2017). https://doi.org/10.1007/s12032-017-0995-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-017-0995-1

Keywords

Search

Navigation